NCT07022483: An ongoing trial by Daiichi Sankyo
This trial is ongoing. It must report results 6 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07022483 |
|---|---|
| Title | A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 30, 2025 |
| Completion date | March 23, 2032 |
| Required reporting date | March 23, 2033, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 15, 2026 |
| Days late | None |